will be made on May 24, 2019. The mentioned right will be further approved by the AGM 2019. 2. Approved to propose to the AGM to consider and approve the financial statement of the company for the fiscal
Consolidated Financial Results 1. Operating Results Revenues In the first half of fiscal year 2021, the total consolidated revenues were 10,386 million baht, decreasing of 655 million baht or 6% y-y. In the
accounts of 10,772 million baht or 12% of total accounts receivable, decreasing from 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. For default receivables in
10,470 million baht or 11% of total accounts receivable, comparing to that of 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. The delinquent account receivables
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
cost was 10.05 Million Baht or an increase of 7.18 Million Baht which is equivalent to an increase of 250.17 % from the previous year. For the period of six months of the fiscal year 2017, the Company's
August 15, 2017 Subject: MD&A for the financial statements of the 2nd quarter of fiscal year 2017 ended as of June 30, 2017 To: The President The Stock Exchange of Thailand Aapico Hitech Public Company
year. For the period of nine months of the fiscal year 2017, the Company's financing cost was 42.48 Million Baht, increased by 32.67 Million Baht, or up by 333.03% from the previous year. The result was